PBAC's latest decision on Capecitabine: Recommended (2011). Considered for adjuvant treatment of stage III (Dukes C) colon cancer, following complete resection of the primary tumour; either as monotherapy or in combination with oxaliplatin.
PBAC outcome
Recommended
Authority required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
4
first 2005
Submissions
4
2005 → 2011
Eligible population
patients with stage III (Dukes C) colon cancer, following complete resection of the primary tumour
Therapy area
Oncology
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
OS | PFS | DFS
Key trials
NO16968, MOSAIC, NSABP C-07
Comparator
modified FOLFOX-6 (oxaliplatin with 5-fluorouracil and folinic acid)
Economic model
Cost-minimisation
Budget impact
$-10000000
ICER note
Cost-minimisation analysis; XELOX associated with cost saving per patient compared to mFOLFOX-6
Submission history
Nov 2005: Recommended with restriction · Authority Required